Genome and network visualization facilitates the analyses of the effects of drugs and mutations on protein-protein and drug-protein networks by Arnaud Céol et al.
RESEARCH ARTICLE Open Access
Genome and network visualization
facilitates the analyses of the effects of
drugs and mutations on protein-protein
and drug-protein networks
Arnaud Céol*, Lisette G. G. C. Verhoef, Mark Wade and Heiko Muller
From NETTAB 2014. From structural bioinformatics to integrative systems biology
Torino, Italy. 15-17 October 2014
Abstract
Background: Biologists generally interrogate genomics data using web-based genome browsers that have limited
analytical potential. New generation genome browsers such as the Integrated Genome Browser (IGB) have largely
overcome this limitation and permit customized analyses to be implemented using plugins. We illustrate the use of
a plugin for IGB that exploits advanced visualization techniques to integrate the analysis of genomics data with
network and structural approaches.
Results: We show how visualization technologies that combine both genomics and network biology can facilitate
the selection of the key amino acid contacts from protein-protein and protein-drug interactions. Starting from the
MDM2-P53 interaction, which is a high-value target for cancer therapy, and Nutlin, the parent small molecule of an
MDM2 antagonist that is currently in clinical trials, we show that this method can be generalized to analyze how
drugs and mutations can interfere with both protein-protein and drug-protein networks. We illustrate this point by
two additional use-cases exploring the molecular basis of tamoxifen side effects and of drug resistance in chronic
myeloid leukemia patients.
Conclusions: Combined network and structure biology approaches provide key insights into both the genetic and
the edgetic roles of variants in diseases. 3D interactomes facilitate the identification of disease-relevant interactions
that can then be specifically targeted by drugs. Recent advances in molecular interaction and structure visualization
tools have greatly simplified the mapping of mutated residues to molecular interaction interfaces. Such approaches
can now also be integrated with genome visualization tools to enable comparative analyses of interaction contacts.
Keywords: Protein networks, Structures, Genome variants, Genome browsing, Visualization, Protein-protein
interaction, Protein-ligand interactions
* Correspondence: arnaud.ceol@iit.it
Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di
Tecnologia (IIT), Via Adamello 16, Milan I-20139, Italy
© 2016 Céol et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Céol et al. BMC Bioinformatics 2016, 17(Suppl 4):54
DOI 10.1186/s12859-016-0908-x
Background
The wealth of available genomics data has created an
analysis bottleneck; efficient means of candidate gene
prioritization that permit the integration, comparison
and interpretation of genome-scale molecular informa-
tion are therefore urgently needed. In particular, network
and structural biology criteria must be applied to candi-
date genes in order to pinpoint their contribution to the
development of cancer-specific phenotypic traits and to
evaluate their druggability. In general terms, the former
can be evaluated by studying the connectivity of candi-
date genes with bona-fide cancer genes in protein-
protein interaction (PPI) networks, while the latter can
be deduced from structural information on the protein
of interest.
Disease networks (networks of disorders and disease
proteins) facilitate the identification of connections be-
tween disease-causing gene defects [1, 2] and mapping
genomic regions to the networks of interactions with
structures (3D networks) allows data-driven hypothesis
generation about mutations that are likely to have edge-
tic effects [3], i.e. a loss or gain of interaction. Protein-
ligand interactions (PLIs) can reveal valuable hints about
the druggability of candidate genes as well as the contact
regions of their binding partners. The development of
drugs interfering with PPIs is challenging due to the na-
ture of the PPI interface. The first successful example
was the 1986 report of peptide-mediated inhibition of
Herpes simplex type I ribonucleotide reductase [4, 5].
Since then, important progress has been made. It has
been recognized that druggable PPIs largely fall into four
different classes [6]. The first class employs short pep-
tide epitopes that are bound by another protein. The
second class is based on secondary structure epitopes
where a single peptide from one protein binds to a
groove presented by the binding partner. The major part
of the binding energy is provided by a small number of
amino acids called hotspots. The third class of PPIs uti-
lizes large and shallow globular regions called tertiary
structure epitopes. The fourth class is based on allosteric
interactions. The second class of PPIs has sparked par-
ticular interest due to the presence of binding pockets
and hotspot amino acids that can be identified by ex-
perimental and computational methods, and whose
function can be disrupted by relatively small compounds
developed using traditional medicinal chemistry [6]. It is
reasonable to assume that hotspot amino acids are pre-
ferred targets of mutations in cancer and other diseases.
Therefore, computational tools facilitating the mapping
of mutations identified in genomic screens to protein
structures are expected to be of considerable help in
identifying hotspots.
Knowledge of the structures of proteins and PPIs is
required to understand the mechanism of action of
drugs and how they interfere with protein networks. The
Protein Data Bank (PDB) [7] contains almost 30,000
structures that include human molecules. Those struc-
tures describe more than 4500 human direct interactions
(estimation based on the number of experimental struc-
tures available in Interactome3D version 2015_05). Al-
though the coverage of the protein network is far from
being complete, high quality models such as those pro-
posed by Interactome3D [8] have extended the human
PPI network with models for 4294 additional human
PPIs. It is important to note that all interactions in Inter-
actome3D, including those based on a model only, are
supported by experimental evidence (e.g., yeast two hy-
brid or co-immunoprecipitation), and that the modeling
framework has been validated to ensure that only high
quality models are provided.
Combining data on protein structures and genomic
screens for integrated analysis is a non-trivial task. We
have recently developed a plugin for IGB [9] that uses
advanced visualization techniques to integrate the ana-
lysis of genomics data with network and structural biol-
ogy approaches [10]. The plugin automatically maps
genomic regions to protein sequence and interaction
structures and identifies residues in contact with pro-
teins, nucleic acids or small molecules. Here we show
how such visualization technologies that combine both
genomics and network biology can be used to map gen-
omic variations to molecular networks, and to identify
hotspots based on protein-protein and protein-drug in-
teractions. This allows the end user to generate hypoth-
eses regarding drug- and ligand-dependent perturbations
of PPI networks, and provides predictions as to how spe-
cific mutations might have an impact on drug resistance.
Results and discussion
Protein-protein and protein-ligand interactions in
structure databases
The PDB contains structures for 5387 human proteins
from UniProt (02/2015) [11]. Those structures describe
the coordinates of either a single molecule or of a com-
plex that can include one or more binding partners (pro-
teins, nucleic acids, drugs or other compounds). Based
on PDB, Interactome3D has built a network of 8880 hu-
man interactions with structure (including experimental
structures and models). Many of the proteins in this 3D
PPI network also interact with drugs and other com-
pounds. We compared the interfaces in PPI structures
to the interfaces of protein-ligand interactions (PLIs).
Our premise was that compounds that share one or
more contact residues with a protein are potentially cap-
able of interfering with the PPI.
We started by retrieving the list of structures from
PDB that include a compound and extracted all contacts
between proteins and ligands (Fig. 1a). Then, we
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inspected all human PPIs in the pre-calculated structural
human network from Interactome3D, including models,
to identify contacts in common with the ligands (residues
with Buried Surface Area > 1 Å2, see methods). We identi-
fied 1253 ligands that bind at the interface of 1123 human
binary PPIs (meaning that at least one contact is shared
with PLI). The interactions are based on 473 complete
experimental structures and 650 complete homology
models (>80 % coverage) or partial experimental struc-
tures or models.
Many of those ligands (for instance solvents, salts,
molecules used for experimental purposes, and cofac-
tors) may be irrelevant when looking for molecules that
may alter the PPI network. Therefore, we restricted the
list of ligands in PDB to include only small molecules
approved by the U.S. Food and Drug Administration
(FDA) listed in DrugBank [12] (see Methods). Of the
1253 interface compounds we identified above, 44 are
approved small molecules that are cross-referenced in
DrugBank. Those 44 drugs are at the interface of 151
PPIs (Fig. 2). None of those compounds were originally
designed to target a PPI. This network contains several
well-known drug targets, including cancer targets such
as EGFR and BRAF. The amino acids in contact with
the drugs are also in contact with many proteins in-
volved in signal transduction (46 %, Gene Ontology en-
richment p-value: 7e–19), in response to stimulus (85 %,
p-value 3e–16), and they are mainly membrane proteins
(72 %, p-value: 8e-7, see Additional file 1 for the
complete list of enriched terms). Interestingly, many of
those contacts have been identified in complete hom-
ology models (68 interactions) or partial experimental
structures or models (14 interactions), rather than in
complete experimental structures (68). Some interactions
have been modeled from the homologs of the interacting
proteins in other closely related species. For example, the
NCOA2-VDR interaction (uniprotkb:Q15596 and uni-
protkb:P11473) was modeled based on a structure that used
the Zebrafish homolog of human VRD (PDB:3o1d). An ex-
perimental structure can also be used to model other
Fig. 1 Pipeline for the comparison of protein-protein and protein-ligand analyses. a General pipeline: the structures for PLIs are downloaded from
PDB and those for PPIs from Interactome3D. We use the BioJava library to extract protein-protein and protein-ligand contacts. Finally, we calculate
the intersection between PPI and PLI contacts to identify the drugs that may interfere with the PPIs. b Visualization and analyses with IGB/MI-Bundle:
we select a gene of interest in IGB and run the plugin twice: 1) on Interactome3D, with the PPI option, 2) on PDB, with the Small Molecules option.
For each query, a result table is generated. We select the PPI and PLI interaction of interest in the respective table and for each of them we press the
“create track” button. The generated tracks show all the residues of the selected protein that are in contact in a given interaction. We select both tracks
and calculate the intersection (right click, then “track operations” and “Intersection”). IGB creates a new track where all residues of the selected protein
that are in contact with the other protein and the small molecule are shown
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interactions in the network. For instance, the model for the
BRAF-RAF1 (uniprotkb:P15056 and uniprotkb:P04049)
interaction is based on the experimental structure of the
BRAF homodimer (PDB: 4ehe,4mbj). Since these results
were able to pinpoint cancer-relevant pathways, and also
predict the influence of small molecules on PPIs, we next
used genome and network visualization to analyze some ex-
amples of drug interactions.
Drugs in protein-protein networks: a visualization
perspective
By intersecting the structural protein-protein and pro-
tein ligand networks above, we observed that many
small molecules, including several approved drugs, could
potentially compete with other proteins for binding at
interaction sites. However, these analyses required pro-
gramming skills, the download of datasets with diverse
formats from external repositories, and basic knowledge
of network and structural biology. To overcome these is-
sues, and make the tool more accessible to a broader sci-
entific user base, we have integrated the analysis pipeline
into a single visualization tool as an IGB plugin called
Molecular Interaction (MI) bundle [10]. Several im-
provements have been implemented and integrated (ver-
sion 2.9 of the plugin), including the option of querying
PDB for ligands only (in previous versions, PPIs were al-
ways included), and the integration of information from
DrugBank (including drug name and ID) if a cross-
reference is available.
Here we used this plugin to visually investigate several
examples of drug-PPI interactions, and to integrate mu-
tations and drug-ligand data in order to identify gate-
keeper mutations (mutations that abrogate binding of
drugs to their targets).
Fig. 2 Network protein-protein interactions with drug binding interface. Network of PPIs whose interface is shared with a drug (from DrugBank).
Dark edges: interactions with complete experimentally determined structure; Orange edges: interactions with complete homology models;
dashed lines: interactions with partial experimental structures or models. Edge label: names of the drugs targeting the protein indicated with a
small black circle. For clarity, the name of the drugs is only indicated on one edge for each target
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The analyses can be done in 5 steps (Fig. 1b):
1) Choose drug target and select the corresponding
gene in IGB,
2) Select PDB and small molecules in the MI-Bundle to
obtain a list of structures with ligands,
3) Select Interactome3D to obtain a list of PPIs with
either a structure or a model,
4) Create a new track for each single interaction of
interest: the PLI and the PPI by clicking on the
“create track” button on the selected row in the
result table,
5) Select tracks of interest and calculate the
intersection using basic IGB functionalities.
We illustrate this pipeline with the examples of the
p53-activating drug Nutlin, the estrogen receptor modu-
lator Tamoxifen, and the development of resistance to
Imatinib in chronic myeloid leukemia patients (see also
Additional file 2: Additional example of drugs targeting
PPIs).
The MDM2-P53 druggable interaction, a case study
P53 is a transcription factor that mediates cell cycle ar-
rest, senescence, or apoptosis in response to DNA dam-
age or oncogenic stress. Consistent with its bona fide
tumor suppressor status, the function of p53 or its regu-
lators is altered in most cancers. The MDM2 oncopro-
tein (uniprotkb: Q00987) is overexpressed in a large
fraction of human tumors, and exerts its activity primar-
ily via inhibition of P53 (uniprotkb: P04637). The N
terminus of P53 is required for its activity as a transcrip-
tion factor; it is also the critical domain required for
binding to MDM2 [13]. Once bound by MDM2, P53
transactivation function is inhibited. Furthermore, the
intrinsic E3 ubiquitin ligase activity of MDM2 leads to
Fig. 3 The small molecule Nutlin interferes with the MDM2-TP53 interaction. a Structure of Nutlin (yellow) binding to MDM2 (green), of the
MDM2 (green)/P53 (blue) complex. The alignment of the structures shows that the P53 peptide and Nutlin interact with the same binding pocket.
b Interaction contacts in the genome browser. The bottom track (black) displays the MDM2 transcripts. The other tracks display the contacts
between MDM2 and one or more molecules. Dark blue tracks: protein-protein contacts from experimental structures. Green track: Nutlin-MDM2
contacts from experimental structure. Turquoise track: interaction between the Nutlin-MDM2 and the P53-MDM2 tracks. Orange tracks: contacts
from models. A zoom on the intersection track evidences several MDM2 residues in contacts with both Nutlin and P53, including G58
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proteasome-dependent P53 degradation. Thus, targeting
of this interaction has received great attention, as it is
expected to reactivate P53 in the ~50 % of tumors that
retain a wild type allele [14].
Starting our pipeline from the MDM2 gene (Fig. 3), we
pinpointed in the MDM2/P53 track several residues im-
portant for the binding between those two molecules; A
cell-based bimolecular luciferase complementation (BiLC)
assay indicates an effect of the mutation of the G58 residue
on the PPI (see Additional file 2: Selection of the key amino
acid contacts from protein-protein and protein-drug inter-
actions for experimental manipulation). Other residues
(e.g. V75) had already been reported in literature [15].
In the list of partners of MDM2, we found the cis-
imidazoline, Nutlin (NUT, CHEBI:46,742), which was
identified during screening of a compound diversity set
performed by Roche [16]. The residues on the intersec-
tion track (MDM2/P53 and MDM2/Nutlin) are the
MDM2 residues that Nutlin shields from p53. These res-
idues are Phe19, Trp23, and Leu26, which are located in
an alpha-helical region of the P53 N terminus that binds
to the N-terminal MDM2 hydrophobic pocket [17]. The
imidazoline scaffold of Nutlin essentially mimics these
three critical P53 residues; the compound therefore
competes with endogenous P53 for binding to MDM2.
In the absence of a structure between MDM2 and P53
and knowing that Nutlin disrupts this interaction, it
would have been possible to exploit our strategy to infer
some of the contact residues between MDM2 and P53.
MDM2 is involved in three additional interactions for
which a structure is available. We created a new track to
display the contacts with each of those: MDM2, USP7
(uniprotkb:Q93009) and MDM4 (uniprotkb:O15151).
Interestingly, the MDM2 homo-dimerization site inter-
sects with the MDM2-Nutlin interface, suggesting that
Nutlin may also interfere with MDM2 homodimeriza-
tion. Conversely, the contacts that MDM2 makes with
USP7 and MDM4 are distinct from the ones with
Nutlin: The MDM2/USP7 and MDM2/MDM4 interac-
tions may not be affected by this ligand, suggesting an
edgetic effect of this compound. Our prediction that
Nutlin does not interfere with the MDM2/MDM4 inter-
action is supported by data showing that MDM2 and
MDM4 co-immunoprecipitate following Nutlin treat-
ment, which is consistent with Nutlin-stimulated,
MDM2-dependant degradation of MDM4 [18, 19].
In order to determine whether Nutlin might perturb
other interactions in which MDM2 participates, we re-
peated the previous query with Interactome3D resulting
in the extension of the 3D coverage of the MDM2 net-
work with models for interactions with three E2 en-
zymes (Ubiquitin-conjugating enzyme E2), UBE2D1
(uniprotkb:P51668), UBE2D2 (uniprotkb:P62837), and
UBE2K (uniprotkb:P61086). Based on the models, none of
Fig. 4 Examples of contact comparison analyses. a Three residues of ESR1 (Asp426, Met522 and Pro535) are involved in the binding with both
Tamoxifen and NR1H4. b Cancer somatic mutations of ABL1-Imatinib contact residues. T315 and F317 are two examples of gatekeeper mutations
involved in drug resistance
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those interactions share contact regions with Nutlin; those
models nevertheless confirm the importance of the C-
terminal MDM2 RING domain in mediating its E3 ubiqui-
tin ligase activity [20]. It is worth noting that the contacts
are based on structures and models that are not
complete, and that additional interfaces may exist.
Another mechanism for tamoxifen action
Intriguingly, our modeling suggests a novel PPI target for
Tamoxifen, a small molecule that is used in the clinic to
treat estrogen-dependent breast cancer [21]. Tamoxifen’s
main mechanism-of-action is to compete with estrogen
for binding to the estrogen receptor (ESR1), thereby pre-
venting the pro-survival and proliferative effects of this
hormone [22]. In addition to steroid hormones, ESR1 has
several protein-binding partners, including NR1H4 (Fig. 2),
a nuclear receptor that regulates the metabolism of
cholesterol, lipid, and glucose. We observed that both
Tamoxifen and NR1H4 share a common binding interface
with ESR1 (Fig. 4a). Following the steps outlined above, an
intersection track confirmed that Tamoxifen and NR1H4
have common contact residues with ESR1. Thus, Tamoxifen
might antagonize the interaction between ESR1 and
NR1H4. This could have functional consequences, since
NR1H4-dependent growth of tumor cell lines in vitro is
dependent on the ESR1/NR1H4 interaction [23].
Mutations inducing drug resistance: the case of imatinib
Although many effective anticancer drugs have been de-
veloped, advances are often hampered by the develop-
ment of drug resistance. There are several mechanisms
that cause drug resistance, including target cell extrinsic
mechanisms, tumor microenvironment, and gene poly-
morphisms that affect gene expression, for instance [24].
Gatekeeper mutations are defined as those that abrogate
binding of drugs to their targets, dramatically reducing
the clinical efficacy of treatment. A classical gatekeeper
mutation causes resistance to Imatinib, a successful
ATP-competitive BCR-ABL kinase inhibitor.
A search for ligands of ABL1 in PDB indicates that the
structure of this protein in contact with Imatinib has
been resolved (PDB: 2hyy and 3pyy). A new track can be
created to display the residues that are actually in con-
tact. We also downloaded from COSMIC [25] a list of
missense mutations and loaded them into the browser.
The comparison of mutated and contact residues identi-
fied several common mutations, which indeed do engen-
der resistance to Imatinib (T315I and F317L) [26].
Importing mutation data in IGB is an easy task. In the
future, in combination with the MI-Bundle, it will be
possible to submit any newly discovered mutation to PLI
analyses to identify new gatekeeper mutations.
Conclusions
Genomics and molecular analysis tools are now widely
available and sufficiently user friendly to allow cross-
disciplinary investigation of the impact of genomic vari-
ants on biological systems. In this manuscript, we have
used an extension for the IGB to illustrate the identifica-
tion of key residues for the binding of MDM2 to P53, of
Tamoxifen to NR1H4, and of gatekeeper mutations in-
ducing resistance to Imatinib. Our IGB plugin greatly
simplifies the integration of genomics data with network
and structural analyses of both protein-protein and PLIs.
The particular example of the MDM2-P53 interaction is
derived from the intersection of 3D protein-protein and
protein-ligand networks. Nevertheless, the structural co-
verage of the protein network is largely incomplete. The
compound-binding proteins we have identified in this work
are involved in many interactions for which no structure is
available. Thus, we are likely missing additional interac-
tions that may be targeted by small molecules. However, it
is possible to increase the structural coverage of the protein
network with Interactome3D, which includes PPI models
for interaction supported by experimental evidence. Al-
though indirect interactions (e.g., in large complexes de-
tected by co-immunoprecipitation) are excluded from the
underlying experimental PPI network in Interactome3D,
false positives may still limit the accuracy of the pipeline.
The score implemented by the MI bundle may help to
identify the most reliable interactions.
By looking at the intersection between protein-ligand
contacts and protein-protein contacts, we were able to
identify small molecules that may interfere with PPIs. To
be clear: our aim with this modeling approach is not to
diminish the importance of the conventional approaches
to discover the mode of action of those drugs. However,
we suggest that our integrated tool can be exploited to
generate new hypotheses. It may also be useful for the
identification of drugs or molecular scaffolds that can be
repurposed in order to block PPIs.
Here, we focused on approved small molecules. Never-
theless, many other ligands have been crystalized to-
gether with target proteins and deposited in PDB,
including experimental molecules and biotech drugs
(peptide, protein or nucleic acid drugs). By extending
the analyses to these additional compounds, we believe
that it will be possible to generate predictions regarding
their effects on disease-relevant PPI networks.
Our analyses are restricted to human proteins. It will be
interesting to extend it to other species, both model organ-
isms (many structures are generated based on the homo-
logs of human proteins), and in host-pathogen interactions.
To this end it may be useful to model not only PPIs, but
also PLIs.
For our initial validation and testing, we have focused our
analyses solely on contact residues, considering that one
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contact may be enough to imply a steric clash when the
two partners are superimposed. We didn’t assess the extent
of cases in which the protein structure of a PLI includes a
protein interface that is significantly different from the
interface between the same protein and another protein
(PPI). We would increase the accuracy of the method by
checking the number of clashing atoms. Indeed, in the ex-
amples based on the MI-bundle, we were able to visually
verify that the respective proteins and drugs share several
residues. This current limitation will also be restrained by
extending the intersection analysis to the entire interaction
interface. Employment of other tools and databases may be
useful in this regard [27, 28]. In addition, it will be interest-
ing to discriminate biological interfaces from crystal arti-
facts. This can be done for instance with the EPPIC server
[28] (see Additional file 2: Selection of the key amino acid
contacts from protein-protein and protein-drug interac-
tions for experimental manipulation).
We have shown that all our analyses can be done
without prior bioinformatics skills by using IGB together
with the MI bundle. The software allows loading,
visualization, comparison, and analysis of protein-protein
and PLIs. Importantly, such analyses are not limited to the
current knowledge deposited in public databases. The MI-
bundle allows a local copy of an Interactome3D directory
to be used. Any user that generates new protein networks
(e.g. by yeast two hybrid) can submit them to the Interac-
tome3D server and download the resulting structural net-
work. Consequently, the user will be able to apply the
plugin to their own data to discover new putative drug-
PPI interactions.
As a genome browser, IGB accepts a large number of
genomic formats, such as BED, VCF or GTF; it can also
communicate directly with DAS servers [29], such as those
implemented by the UCSC Genome Browser [30, 31] or
Ensembl [32]. Therefore, it is easy to interrogate newly dis-
covered mutations for their potential to induce drug resist-
ance (gatekeeper mutations).
Finally, we did not consider the features of PPIs that
may influence the success of an inhibitor in this manu-
script. In a recent review, Smith and Gestwicki [6] have
analyzed how amenable each of the four PPI classes are to
inhibition, according to whether the interface is classified
as “Loose” or “Tight”, and “Wide” or "Narrow". Integrating
this information in our frameworks will facilitate the iden-
tification of the most promising PPI targets.
Methods
Drugs and compounds
We used the mapping file available at [33] to associate
the compounds in the structures to DrugBank IDs
(DrugBank version 4.2) [12]. This file only contains ap-
proved drugs. We downloaded the file [34] to obtain the
list of known targets from DrugBank.
We used the mapping between Uniprot and PDB pro-
vided by the SIFTS initiative [35].
Structures
We worked on a local mirror of the PDB database up-
dated on May 2015. For PPIs, we downloaded the rep-
resentative human dataset from Interactome3D, version
2015_05. The structures in Fig. 3 have been aligned and
displayed with the UCSF Chimera package [36].
Contacts
In order to identify the contacts between the pairs of
proteins or the pairs of protein-compound identified in
the previous step, we measure the available buried sur-
face area as described in [10]. We consider as contact all
residues with Buried Surface Area > 1 Å2. Parsing of
PDB files and calculation of the available surface area
was done with the BioJava libraries version 4.1 [37].
Mutation data
We have downloaded the VCF file of all coding muta-
tions in Cosmic [25] version 4.1 for the human reference
genome version GRCh38 from [38].
Network visualization
The network figures have been generated with Cytoscape
version 3.2.0 [39].
Gene ontology enrichment
We used the BINGO plugin [40] for Cytoscape to
obtain GO enrichments on the list of partners of the
drug targets. To avoid a bias toward proteins with
structures, we used as reference set all the human
proteins included in the human 3D network of Inter-
actome3D. We downloaded from GOA [41] the GO
annotations for human (generated: 2015-07-20). We
used the GOA slim ontology in order to obtain a
smaller list of GO terms that covers all GO categories
(Biological Processes, Molecular Function, Cellular
Compartment).
Analyses with IGB and the MI-bundle
We downloaded and installed IGB and the MI-Bundle as
described at [42]. All analyses in IGB are done on the
human reference genome version GRCh38.
Additional files
Additional file 1: Additional table: Gene Ontology terms enriched
in the partners of drug targets. (PDF 58 kb)
Additional file 2: Additional results: Selection of the key amino acid
contacts from protein-protein and protein-drug interactions for ex-
perimental manipulation; Additional example of drugs targeting
PPIs. (PDF 499 kb)
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